These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Monoclonal antibodies against transitional cell carcinoma assay tumor associated antigens in different grades bladder cancer patients].
    Author: Zhang H, Zhao Z, Sun H.
    Journal: Zhonghua Wai Ke Za Zhi; 1996 Sep; 34(9):560-2. PubMed ID: 9594163.
    Abstract:
    Monoclonal antibodies (McAb) 19A211, M344 against transitional cell carcinoma (TCC) was used to assay the tumor associated antigens on paraffin-embedded tissue sections of 51 different grades bladder cancer patients with immunohistochemical stain method. The positive rates of 19A211, M344 antigens expression were 82.4% and 88.2% in 17 grade I patients 77.7% and 83.3% in 18 grade II patients, 37.5% and 37.5% in 16 grade III patients. 19A211 and M344 antigens expression in statistical analysis was as follows: 19A211, grade I/grade III, P < 0.01, grade II/grade II, P < 0.05, M344, grade I/grade III, P < 0.01, grade II/grade II, P < 0.05, showed significant differences. Combined use of McAb 19A211 and M344 assay bladder TCC tumor associated antigens, showed that the positive rates of antigen expression in grade I was 100% (17/17), in grade II was 88.8% (16/18), in grade III was 68.8% (11/16). The results indicate that McAb 19A211, M344 were fit to diagnose grade I, II bladder TCC. Using both of two McAb can increase the positive rate in finding superficial bladder TTC.
    [Abstract] [Full Text] [Related] [New Search]